Skip to main content

Eikon Therapeutics, Inc.

corporate_fare Company Profile

Eikon Therapeutics, Inc.

EIKN·NASDAQ·Life Sciences·CIK 0001861123

Eikon Therapeutics, Inc. is a late-stage clinical biopharmaceutical company building a global, fully-integrated organization to develop innovative medicines addressing serious unmet medical needs. Its initial focus is oncology, where it is advancing a pipeline of drug candidates targeting areas of high unmet need in large indications. The company's strategy centers on deploying its technology platform, including its proprietary single molecule tracking (SMT) system, to develop internally-derived novel therapies, while also using its management team's expertise to opportunistically in-license promising assets. Its most advanced product candidate, EIK1001, a toll-like receptor (TLR) 7/8 dual-agonist, is in a global Phase 2/3 registrational trial in combination with pembrolizumab for the treatment of patients with advanced melanoma. The company is led by Chair and Chief Executive Officer Dr. Roger M. Perlmutter, M.D., Ph.D., and Chief Medical Officer Dr. Roy Baynes, M.D., Ph.D., who have a track record of identifying, developing, and commercializing impactful drugs, including pembrolizumab. Its broader leadership team consists of former senior leaders at global pharmaceutical companies who have collaborated on the discovery, development, and commercialization of over 100 new molecular entities.

Eikon Therapeutics, Inc. (NASDAQ:EIKN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for EIKN at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Eikon Therapeutics Completes Initial Public Offering, Raising $349 Million Net to Fund Clinical Pipeline
$4.74
52-week range · as of 2026-10-26 $4.74 – $17.4
Market cap
$256.84M
Volume
691.4K (1.3× avg)
3-mo avg 523.5K
Live data · 2026-11-22 12:49 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed EIKN - Filings & News (Page 2)

EIKN
Feb 05, 2026, 4:05 PM EST
Filing Type: 424B4
Importance Score:
8
Price at Filing: $14.70
Real-time Price: $4.74 info
Change: -$9.96 (-68%) info
Market Cap: $256.842M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets